IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Original): A peptide which comprises any one of the amino acid sequences selected from a group consisting of:

Arg Tyr Phe Pro Asn Ala Pro Tyr Leu (SEQ ID NO: 2),

Arg Tyr Pro Gly Val Ala Pro Thr Leu (SEQ ID NO: 3),

Arg Tyr Pro Ser Cys Gln Lys Lys Phe (SEQ ID NO: 4),

Ala Tyr Leu Pro Ala Val Pro Ser Leu, (SEQ ID NO: 5), and

Asn Tyr Met Asn Leu Gly Ala Thr Leu. (SEQ ID NO: 6).

Claim 2 (Original): The peptide according to claim 1, which consists of any one of the amino acid sequences selected from a group consisting of SEQ ID NOs: 2, 3, 4, 5, and 6.

Claim 3 (Original): A peptide which comprises an altered amino acid sequence wherein an alteration of an amino acid residue is comprised in any one of the amino acid sequences selected from a group consisting of SEQ ID NOs: 2, 3, 4, 5, and 6, and which has an activity to induce a CTL in an HLA-A24-restricted manner, except for a peptide comprising the amino acid of SEQ ID NO: 7.

Claim 4 (Original): The peptide according to claim 3, which comprises an altered amino acid sequence wherein leucine at position 9 in any one of the amino acid sequences selected from a group consisting of SEQ ID NOs: 2, 3, 5, and 6 is substituted by phenylalanine, tryptophan, isoleucine, or methionine.

Reply to Restriction Requirement of April 12, 2007

Claim 5 (Original): The peptide according to claim 3, which comprises an altered

amino acid sequence wherein phenylalanine at position 9 in the amino acid sequence of SEQ

ID NO: 4 is substituted by tryptophan, leucine, isoleucine, or methionine.

Claim 6 (Original): The peptide according to claim 3, which comprises an altered

amino acid sequence wherein cysteine at position 5 in the amino acid sequence of SEQ ID

NO: 4 is substituted by alanine, serine, or α -aminobutyric acid (SEQ ID NO: 66, 67, or 68).

Claims 7-17 (Canceled).

Claim 18 (Previously Presented): A pharmaceutical composition which comprises

the peptide according to claim 1 or claim 3, together with a pharmaceutically acceptable

carrier.

Claim 19 (Previously Presented): A cancer vaccine which comprises as an effective

ingredient the peptide according to claim 1.

Claims 20-36 (Canceled).

Claim 37 (New): An isolated peptide of SEQ ID NO: 2.

3